A blood sign linked to Alzheimer’s may predict the risk of declining thinking abilities

A blood sign linked to Alzheimer’s may predict the risk of declining thinking abilities

A blood test measuring a protein associated with Alzheimer’s may help estimate an older adult’s risk of cognitive decline over the next five to 10 years, a Mayo Clinic study published in JAMA Neurology reports.

Researchers examined levels of phosphorylated tau 217, or p-tau217, in 2,178 adults ages 60 to 90 who had no cognitive impairment. They also took into account participants’ ages, sexes and whether they carried the APOE ε4 gene variant, which is linked to Alzheimer’s risk.

Participants in the Mayo Clinic Study of Aging and the Alzheimer’s Disease Neuroimaging Initiative had blood and genetic tests, along with repeated cognitive assessments.

After accounting for p-tau217 levels, APOE ε4 was only modestly associated with risk. Age, however, made a substantial difference, the researchers found.

For instance, among people with the same elevated p-tau217 level, the estimated five-year risk of mild cognitive impairment was 6% for someone aged 65, compared with 37% for someone aged 85.

Alzheimer’s involves plaques and tangles that build up in the brain. The blood test can detect p-tau217, a marker associated with this underlying pathology; higher levels are linked to a greater chance of progressing from normal cognition to impairment.

Testing blood for p-tau217 may be less invasive and easier to scale than PET scans, which can measure amyloid buildup, another feature of Alzheimer’s associated with later cognitive impairment.

The researchers said their aim is to offer people a personalized estimate of cognitive impairment risk, rather than simply labeling an amyloid blood test as positive or negative.

The results could become more useful if treatments are developed and approved to prevent or delay cognitive decline. In that case, risk estimates might help patients and clinicians weigh possible treatment benefits and harms.

For now, the prediction model is not ready for routine screening of people without cognitive symptoms. The study also does not show that regular blood testing prevents dementia or improves health outcomes. There is currently no approved treatment for people who have Alzheimer’s-related changes in the brain but no symptoms, the researchers noted.

The estimates were developed using participants from a particular region of southeastern Minnesota, which may not represent the wider U.S. population. The researchers said the findings need to be tested in other groups.

Having Alzheimer’s-related pathology does not necessarily mean a person will develop symptoms. Some older adults with lower levels of the pathology may never experience cognitive impairment, and others may die of unrelated causes first.

Facebook
Twitter
LinkedIn
Reddit
Telegram
WhatsApp

Related News